Evaluation of drug‐drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically‐based pharmacokinetic model
Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure. In vitro, OM is an inhibitor of BCRP. Rosuvastatin, a BCRP substrate, is one of the most commonly prescribed medications in patients with heart failure. The potential for a pharmacokinetic...
Saved in:
| Published in | Clinical and translational science Vol. 14; no. 6; pp. 2510 - 2520 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
United States
John Wiley & Sons, Inc
01.11.2021
John Wiley and Sons Inc Wiley |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1752-8054 1752-8062 1752-8062 |
| DOI | 10.1111/cts.13118 |
Cover
Loading…
| Abstract | Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure. In vitro, OM is an inhibitor of BCRP. Rosuvastatin, a BCRP substrate, is one of the most commonly prescribed medications in patients with heart failure. The potential for a pharmacokinetic (PK) drug‐drug interaction (DDI) was investigated, specifically to determine whether a single 50 mg dose of OM would impact the PKs of a single 10 mg dose of rosuvastatin in an open‐label study in 14 healthy subjects. The ratios of the geometric least‐square means (90% confidence intervals [CIs]) of rosuvastatin co‐administered with OM compared to rosuvastatin alone were 127.1% (90% CI 113.8–141.9), 132.8% (90% CI 120.7–146.1), and 154.2% (90% CI 132.8–179.1) for area under the plasma‐concentration time curve from time zero to infinity (AUCinf), area under the plasma‐concentration time curve from time zero to time of last quantifiable concentration (AUClast), and maximum observed plasma concentration (Cmax), respectively. Whereas the DDI study with rosuvastatin was conducted with the co‐administration of a single dose of OM, in the clinical setting, patients receive OM at doses of 25, 37.5, or 50 mg twice daily (b.i.d.). Hence, to extrapolate the results of the DDI study to a clinically relevant scenario of continuous b.i.d. dosing with OM, physiologically‐based pharmacokinetic (PBPK) modeling was performed to explore the potential of BCRP inhibition following continuous b.i.d. dosing of OM at the highest 50 mg dose. Modeling results indicated that following 50 mg b.i.d. dosing of OM, the predicted ratios of the geometric means (90% CIs) for rosuvastatin AUCinf and Cmax were 1.18 (90% CI 1.16–1.20) and 2.04 (90% CI 1.99–2.10), respectively. Therefore, these results suggest that OM, following multiple dose administration, is a weak inhibitor of BCRP substrates and is in accordance with that observed in the single dose OM DDI clinical study. |
|---|---|
| AbstractList | Abstract Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure. In vitro, OM is an inhibitor of BCRP. Rosuvastatin, a BCRP substrate, is one of the most commonly prescribed medications in patients with heart failure. The potential for a pharmacokinetic (PK) drug‐drug interaction (DDI) was investigated, specifically to determine whether a single 50 mg dose of OM would impact the PKs of a single 10 mg dose of rosuvastatin in an open‐label study in 14 healthy subjects. The ratios of the geometric least‐square means (90% confidence intervals [CIs]) of rosuvastatin co‐administered with OM compared to rosuvastatin alone were 127.1% (90% CI 113.8–141.9), 132.8% (90% CI 120.7–146.1), and 154.2% (90% CI 132.8–179.1) for area under the plasma‐concentration time curve from time zero to infinity (AUCinf), area under the plasma‐concentration time curve from time zero to time of last quantifiable concentration (AUClast), and maximum observed plasma concentration (Cmax), respectively. Whereas the DDI study with rosuvastatin was conducted with the co‐administration of a single dose of OM, in the clinical setting, patients receive OM at doses of 25, 37.5, or 50 mg twice daily (b.i.d.). Hence, to extrapolate the results of the DDI study to a clinically relevant scenario of continuous b.i.d. dosing with OM, physiologically‐based pharmacokinetic (PBPK) modeling was performed to explore the potential of BCRP inhibition following continuous b.i.d. dosing of OM at the highest 50 mg dose. Modeling results indicated that following 50 mg b.i.d. dosing of OM, the predicted ratios of the geometric means (90% CIs) for rosuvastatin AUCinf and Cmax were 1.18 (90% CI 1.16–1.20) and 2.04 (90% CI 1.99–2.10), respectively. Therefore, these results suggest that OM, following multiple dose administration, is a weak inhibitor of BCRP substrates and is in accordance with that observed in the single dose OM DDI clinical study. Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure. In vitro, OM is an inhibitor of BCRP. Rosuvastatin, a BCRP substrate, is one of the most commonly prescribed medications in patients with heart failure. The potential for a pharmacokinetic (PK) drug‐drug interaction (DDI) was investigated, specifically to determine whether a single 50 mg dose of OM would impact the PKs of a single 10 mg dose of rosuvastatin in an open‐label study in 14 healthy subjects. The ratios of the geometric least‐square means (90% confidence intervals [CIs]) of rosuvastatin co‐administered with OM compared to rosuvastatin alone were 127.1% (90% CI 113.8–141.9), 132.8% (90% CI 120.7–146.1), and 154.2% (90% CI 132.8–179.1) for area under the plasma‐concentration time curve from time zero to infinity (AUCinf), area under the plasma‐concentration time curve from time zero to time of last quantifiable concentration (AUClast), and maximum observed plasma concentration (Cmax), respectively. Whereas the DDI study with rosuvastatin was conducted with the co‐administration of a single dose of OM, in the clinical setting, patients receive OM at doses of 25, 37.5, or 50 mg twice daily (b.i.d.). Hence, to extrapolate the results of the DDI study to a clinically relevant scenario of continuous b.i.d. dosing with OM, physiologically‐based pharmacokinetic (PBPK) modeling was performed to explore the potential of BCRP inhibition following continuous b.i.d. dosing of OM at the highest 50 mg dose. Modeling results indicated that following 50 mg b.i.d. dosing of OM, the predicted ratios of the geometric means (90% CIs) for rosuvastatin AUCinf and Cmax were 1.18 (90% CI 1.16–1.20) and 2.04 (90% CI 1.99–2.10), respectively. Therefore, these results suggest that OM, following multiple dose administration, is a weak inhibitor of BCRP substrates and is in accordance with that observed in the single dose OM DDI clinical study. Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure. In vitro, OM is an inhibitor of BCRP. Rosuvastatin, a BCRP substrate, is one of the most commonly prescribed medications in patients with heart failure. The potential for a pharmacokinetic (PK) drug‐drug interaction (DDI) was investigated, specifically to determine whether a single 50 mg dose of OM would impact the PKs of a single 10 mg dose of rosuvastatin in an open‐label study in 14 healthy subjects. The ratios of the geometric least‐square means (90% confidence intervals [CIs]) of rosuvastatin co‐administered with OM compared to rosuvastatin alone were 127.1% (90% CI 113.8–141.9), 132.8% (90% CI 120.7–146.1), and 154.2% (90% CI 132.8–179.1) for area under the plasma‐concentration time curve from time zero to infinity (AUC inf ), area under the plasma‐concentration time curve from time zero to time of last quantifiable concentration (AUC last ), and maximum observed plasma concentration (C max ), respectively. Whereas the DDI study with rosuvastatin was conducted with the co‐administration of a single dose of OM, in the clinical setting, patients receive OM at doses of 25, 37.5, or 50 mg twice daily (b.i.d.). Hence, to extrapolate the results of the DDI study to a clinically relevant scenario of continuous b.i.d. dosing with OM, physiologically‐based pharmacokinetic (PBPK) modeling was performed to explore the potential of BCRP inhibition following continuous b.i.d. dosing of OM at the highest 50 mg dose. Modeling results indicated that following 50 mg b.i.d. dosing of OM, the predicted ratios of the geometric means (90% CIs) for rosuvastatin AUC inf and C max were 1.18 (90% CI 1.16–1.20) and 2.04 (90% CI 1.99–2.10), respectively. Therefore, these results suggest that OM, following multiple dose administration, is a weak inhibitor of BCRP substrates and is in accordance with that observed in the single dose OM DDI clinical study. Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure. In vitro, OM is an inhibitor of BCRP. Rosuvastatin, a BCRP substrate, is one of the most commonly prescribed medications in patients with heart failure. The potential for a pharmacokinetic (PK) drug‐drug interaction (DDI) was investigated, specifically to determine whether a single 50 mg dose of OM would impact the PKs of a single 10 mg dose of rosuvastatin in an open‐label study in 14 healthy subjects. The ratios of the geometric least‐square means (90% confidence intervals [CIs]) of rosuvastatin co‐administered with OM compared to rosuvastatin alone were 127.1% (90% CI 113.8–141.9), 132.8% (90% CI 120.7–146.1), and 154.2% (90% CI 132.8–179.1) for area under the plasma‐concentration time curve from time zero to infinity (AUCinf), area under the plasma‐concentration time curve from time zero to time of last quantifiable concentration (AUClast), and maximum observed plasma concentration (Cmax), respectively. Whereas the DDI study with rosuvastatin was conducted with the co‐administration of a single dose of OM, in the clinical setting, patients receive OM at doses of 25, 37.5, or 50 mg twice daily (b.i.d.). Hence, to extrapolate the results of the DDI study to a clinically relevant scenario of continuous b.i.d. dosing with OM, physiologically‐based pharmacokinetic (PBPK) modeling was performed to explore the potential of BCRP inhibition following continuous b.i.d. dosing of OM at the highest 50 mg dose. Modeling results indicated that following 50 mg b.i.d. dosing of OM, the predicted ratios of the geometric means (90% CIs) for rosuvastatin AUCinf and Cmax were 1.18 (90% CI 1.16–1.20) and 2.04 (90% CI 1.99–2.10), respectively. Therefore, these results suggest that OM, following multiple dose administration, is a weak inhibitor of BCRP substrates and is in accordance with that observed in the single dose OM DDI clinical study. Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure. In vitro, OM is an inhibitor of BCRP. Rosuvastatin, a BCRP substrate, is one of the most commonly prescribed medications in patients with heart failure. The potential for a pharmacokinetic (PK) drug-drug interaction (DDI) was investigated, specifically to determine whether a single 50 mg dose of OM would impact the PKs of a single 10 mg dose of rosuvastatin in an open-label study in 14 healthy subjects. The ratios of the geometric least-square means (90% confidence intervals [CIs]) of rosuvastatin co-administered with OM compared to rosuvastatin alone were 127.1% (90% CI 113.8-141.9), 132.8% (90% CI 120.7-146.1), and 154.2% (90% CI 132.8-179.1) for area under the plasma-concentration time curve from time zero to infinity (AUC ), area under the plasma-concentration time curve from time zero to time of last quantifiable concentration (AUC ), and maximum observed plasma concentration (C ), respectively. Whereas the DDI study with rosuvastatin was conducted with the co-administration of a single dose of OM, in the clinical setting, patients receive OM at doses of 25, 37.5, or 50 mg twice daily (b.i.d.). Hence, to extrapolate the results of the DDI study to a clinically relevant scenario of continuous b.i.d. dosing with OM, physiologically-based pharmacokinetic (PBPK) modeling was performed to explore the potential of BCRP inhibition following continuous b.i.d. dosing of OM at the highest 50 mg dose. Modeling results indicated that following 50 mg b.i.d. dosing of OM, the predicted ratios of the geometric means (90% CIs) for rosuvastatin AUC and C were 1.18 (90% CI 1.16-1.20) and 2.04 (90% CI 1.99-2.10), respectively. Therefore, these results suggest that OM, following multiple dose administration, is a weak inhibitor of BCRP substrates and is in accordance with that observed in the single dose OM DDI clinical study. Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure. In vitro, OM is an inhibitor of BCRP. Rosuvastatin, a BCRP substrate, is one of the most commonly prescribed medications in patients with heart failure. The potential for a pharmacokinetic (PK) drug-drug interaction (DDI) was investigated, specifically to determine whether a single 50 mg dose of OM would impact the PKs of a single 10 mg dose of rosuvastatin in an open-label study in 14 healthy subjects. The ratios of the geometric least-square means (90% confidence intervals [CIs]) of rosuvastatin co-administered with OM compared to rosuvastatin alone were 127.1% (90% CI 113.8-141.9), 132.8% (90% CI 120.7-146.1), and 154.2% (90% CI 132.8-179.1) for area under the plasma-concentration time curve from time zero to infinity (AUCinf ), area under the plasma-concentration time curve from time zero to time of last quantifiable concentration (AUClast ), and maximum observed plasma concentration (Cmax ), respectively. Whereas the DDI study with rosuvastatin was conducted with the co-administration of a single dose of OM, in the clinical setting, patients receive OM at doses of 25, 37.5, or 50 mg twice daily (b.i.d.). Hence, to extrapolate the results of the DDI study to a clinically relevant scenario of continuous b.i.d. dosing with OM, physiologically-based pharmacokinetic (PBPK) modeling was performed to explore the potential of BCRP inhibition following continuous b.i.d. dosing of OM at the highest 50 mg dose. Modeling results indicated that following 50 mg b.i.d. dosing of OM, the predicted ratios of the geometric means (90% CIs) for rosuvastatin AUCinf and Cmax were 1.18 (90% CI 1.16-1.20) and 2.04 (90% CI 1.99-2.10), respectively. Therefore, these results suggest that OM, following multiple dose administration, is a weak inhibitor of BCRP substrates and is in accordance with that observed in the single dose OM DDI clinical study.Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure. In vitro, OM is an inhibitor of BCRP. Rosuvastatin, a BCRP substrate, is one of the most commonly prescribed medications in patients with heart failure. The potential for a pharmacokinetic (PK) drug-drug interaction (DDI) was investigated, specifically to determine whether a single 50 mg dose of OM would impact the PKs of a single 10 mg dose of rosuvastatin in an open-label study in 14 healthy subjects. The ratios of the geometric least-square means (90% confidence intervals [CIs]) of rosuvastatin co-administered with OM compared to rosuvastatin alone were 127.1% (90% CI 113.8-141.9), 132.8% (90% CI 120.7-146.1), and 154.2% (90% CI 132.8-179.1) for area under the plasma-concentration time curve from time zero to infinity (AUCinf ), area under the plasma-concentration time curve from time zero to time of last quantifiable concentration (AUClast ), and maximum observed plasma concentration (Cmax ), respectively. Whereas the DDI study with rosuvastatin was conducted with the co-administration of a single dose of OM, in the clinical setting, patients receive OM at doses of 25, 37.5, or 50 mg twice daily (b.i.d.). Hence, to extrapolate the results of the DDI study to a clinically relevant scenario of continuous b.i.d. dosing with OM, physiologically-based pharmacokinetic (PBPK) modeling was performed to explore the potential of BCRP inhibition following continuous b.i.d. dosing of OM at the highest 50 mg dose. Modeling results indicated that following 50 mg b.i.d. dosing of OM, the predicted ratios of the geometric means (90% CIs) for rosuvastatin AUCinf and Cmax were 1.18 (90% CI 1.16-1.20) and 2.04 (90% CI 1.99-2.10), respectively. Therefore, these results suggest that OM, following multiple dose administration, is a weak inhibitor of BCRP substrates and is in accordance with that observed in the single dose OM DDI clinical study. |
| Author | Jafarinasabian, Pegah Trivedi, Ashit Zhang, Hanze Wahlstrom, Jan Spring, Marintan Kulkarni, Priyanka Flach, Stephen Dutta, Sandeep Abbasi, Siddique Lee, Edward Sohn, Winnie |
| AuthorAffiliation | 1 Amgen, Inc Thousand Oaks California USA 3 Present address: Takeda Inc. Cambridge Massachusetts USA 2 Covance Inc Madison Wisconsin USA |
| AuthorAffiliation_xml | – name: 1 Amgen, Inc Thousand Oaks California USA – name: 2 Covance Inc Madison Wisconsin USA – name: 3 Present address: Takeda Inc. Cambridge Massachusetts USA |
| Author_xml | – sequence: 1 givenname: Ashit surname: Trivedi fullname: Trivedi, Ashit email: ashitt@amgen.com organization: Amgen, Inc – sequence: 2 givenname: Winnie surname: Sohn fullname: Sohn, Winnie organization: Amgen, Inc – sequence: 3 givenname: Priyanka surname: Kulkarni fullname: Kulkarni, Priyanka organization: Amgen, Inc – sequence: 4 givenname: Pegah surname: Jafarinasabian fullname: Jafarinasabian, Pegah organization: Amgen, Inc – sequence: 5 givenname: Hanze surname: Zhang fullname: Zhang, Hanze organization: Amgen, Inc – sequence: 6 givenname: Marintan surname: Spring fullname: Spring, Marintan organization: Amgen, Inc – sequence: 7 givenname: Stephen surname: Flach fullname: Flach, Stephen organization: Covance Inc – sequence: 8 givenname: Siddique surname: Abbasi fullname: Abbasi, Siddique organization: Amgen, Inc – sequence: 9 givenname: Jan surname: Wahlstrom fullname: Wahlstrom, Jan organization: Amgen, Inc – sequence: 10 givenname: Edward surname: Lee fullname: Lee, Edward organization: Amgen, Inc – sequence: 11 givenname: Sandeep surname: Dutta fullname: Dutta, Sandeep organization: Amgen, Inc |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34415673$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9ks1u1DAQgCNURH_gwAsgS1xA6raOkzjxBQlWBSpVAkE5RxN7suvFsRfb2dXeeASejUfgSfDulopWAl9sjb_5PLbnODuwzmKWPc3pWZ7GuYzhLC_yvHmQHeV1xSYN5ezgdl2Vh9lxCAtKecGb6lF2WJRlXvG6OMp-XqzAjBC1s8T1RPlx9uv7j-1EtI3oQe62li6ijRoM6TCuERM8oIQh6hXZLnynDQGriHdhXEGIyWhPCZA3008fSRi7ED1EPCVrHecpLI22WiZdiKPapKPIHMHE-WbLLjBdaGcbg7azhC_nm6CdcbNtjtmkCjsIqFIc_ADSfdUWo5ZkcArN4-xhDybgk5v5JPvy9uJ6-n5y9eHd5fT11URWVDSTmmEuSik7xRshkXWC1aJjXU25KjkFqqpCFdCovhF9xXkvREcrYAXHvqC0L06yy71XOVi0S68H8JvWgW53AednLfhUlcG24QAMRQ09K0qhuBCCF7TmtGsUVlwk16u9azl2AyqZHtuDuSO9u2P1vJ25VTLTkpU0CV7cCLz7NmKI7aCDRGPAohtDyypelIzltEzo83vowo3epqdKlBBUiFLUiXr2d0W3pfxpnQS83AMy_Xnw2N8iOW23bdmmX2x3bZnY83us1HHXdOky2vwvY60Nbv6tbqfXn_cZvwEouPrA |
| CitedBy_id | crossref_primary_10_1097_FJC_0000000000001207 crossref_primary_10_1007_s40268_024_00488_0 crossref_primary_10_1016_j_xphs_2023_08_018 crossref_primary_10_1124_dmd_123_001384 crossref_primary_10_3389_fcvm_2024_1337154 crossref_primary_10_3390_membranes14110223 |
| Cites_doi | 10.1517/13543784.2016.1123248 10.1016/0006-2952(73)90196-2 10.1007/164_2017_13 10.1126/science.1200113 10.1002/cpt.1013 10.1016/S0140-6736(16)32049-9 10.1056/NEJMoa2025797 10.1016/j.jchf.2019.12.001 10.7573/dic.212518 10.1007/s10741-009-9135-0 10.1517/17425250802691074 10.1007/s11883-019-0800-z 10.1016/S0140-6736(11)61219-1 10.1124/dmd.112.050500 10.5414/CP202458 10.1124/dmd.117.075606 |
| ContentType | Journal Article |
| Copyright | 2021 Amgen Inc. published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics 2021 Amgen Inc. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. 2021. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2021 Amgen Inc. published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics – notice: 2021 Amgen Inc. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. – notice: 2021. This work is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | 24P AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7QP 7T5 7TK 7TM 7U9 7X7 7XB 8FD 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ H94 HCIFZ K9. LK8 M0S M7N M7P P64 PHGZM PHGZT PIMPY PKEHL PQEST PQGLB PQQKQ PQUKI PRINS RC3 7X8 5PM DOA |
| DOI | 10.1111/cts.13118 |
| DatabaseName | Wiley Online Library Open Access CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Calcium & Calcified Tissue Abstracts Immunology Abstracts Neurosciences Abstracts Nucleic Acids Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Technology Research Database ProQuest SciTech Collection ProQuest Natural Science Collection ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) Biological Sciences ProQuest Health & Medical Collection Algology Mycology and Protozoology Abstracts (Microbiology C) ProQuest Biological Science Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest Central Student Technology Research Database ProQuest One Academic Middle East (New) ProQuest Central Essentials Nucleic Acids Abstracts ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences Genetics Abstracts Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Collection AIDS and Cancer Research Abstracts ProQuest Central (New) Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Immunology Abstracts Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | Publicly Available Content Database CrossRef MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: 24P name: Wiley Online Library Open Access url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html sourceTypes: Publisher – sequence: 3 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 4 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 5 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | DDI EFFECT OF OMECAMTIV MECARBIL ON BCRP SUBSTRATE |
| EISSN | 1752-8062 |
| EndPage | 2520 |
| ExternalDocumentID | oai_doaj_org_article_86aa2e97af2349d6999630760b8de569 PMC8604240 34415673 10_1111_cts_13118 CTS13118 |
| Genre | article Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GroupedDBID | --- 05W 0R~ 10A 1OC 24P 29B 31~ 4.4 52S 53G 5GY 5VS 7X7 8-1 8FE 8FH 8FI 8FJ AAHHS AANHP AAZKR ABDBF ABUWG ACBWZ ACCFJ ACCMX ACRPL ACUHS ACXQS ACYXJ ADKYN ADNMO ADZMN ADZOD AEEZP AEQDE AFBPY AFKRA AFZJQ AIWBW AJBDE ALIPV ALMA_UNASSIGNED_HOLDINGS ALUQN AVUZU BBNVY BDRZF BENPR BHPHI BPHCQ BRXPI BVXVI CAG CCPQU COF CS3 DIK EBD EBS EJD EMOBN ESX F5P FEDTE FYUFA G-S GODZA GROUPED_DOAJ HCIFZ HMCUK HVGLF HYE HZ~ IAO IHR ITC KQ8 LH4 LK8 LW6 M7P MY~ O9- OIG OK1 P2P PIMPY PQQKQ PROAC QB0 ROL RPM SUPJJ SV3 TUS UKHRP WIN XG1 AAYXX AGQPQ CITATION PHGZM PHGZT CGR CUY CVF ECM EIF NPM 3V. 7QP 7T5 7TK 7TM 7U9 7XB 8FD 8FK AZQEC DWQXO FR3 GNUQQ H94 K9. M7N P64 PKEHL PQEST PQGLB PQUKI PRINS RC3 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c5098-72e194ccbd689ce2b9279b2b706d460a0d53d3a8df89f566f99b05a236ef300f3 |
| IEDL.DBID | DOA |
| ISSN | 1752-8054 1752-8062 |
| IngestDate | Wed Aug 27 01:32:23 EDT 2025 Thu Aug 21 18:36:28 EDT 2025 Fri Jul 11 05:05:45 EDT 2025 Wed Aug 13 05:09:14 EDT 2025 Wed Feb 19 02:27:22 EST 2025 Tue Jul 01 01:05:37 EDT 2025 Thu Apr 24 22:58:55 EDT 2025 Wed Jan 22 16:28:36 EST 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 6 |
| Language | English |
| License | Attribution-NonCommercial 2021 Amgen Inc. Clinical and Translational Science published by Wiley Periodicals LLC on behalf of American Society for Clinical Pharmacology and Therapeutics. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c5098-72e194ccbd689ce2b9279b2b706d460a0d53d3a8df89f566f99b05a236ef300f3 |
| Notes | Funding information This study was funded by Amgen, Inc. ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://doaj.org/article/86aa2e97af2349d6999630760b8de569 |
| PMID | 34415673 |
| PQID | 2599099497 |
| PQPubID | 2029979 |
| PageCount | 11 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_86aa2e97af2349d6999630760b8de569 pubmedcentral_primary_oai_pubmedcentral_nih_gov_8604240 proquest_miscellaneous_2563422104 proquest_journals_2599099497 pubmed_primary_34415673 crossref_primary_10_1111_cts_13118 crossref_citationtrail_10_1111_cts_13118 wiley_primary_10_1111_cts_13118_CTS13118 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | November 2021 |
| PublicationDateYYYYMMDD | 2021-11-01 |
| PublicationDate_xml | – month: 11 year: 2021 text: November 2021 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States – name: Hoboken |
| PublicationTitle | Clinical and translational science |
| PublicationTitleAlternate | Clin Transl Sci |
| PublicationYear | 2021 |
| Publisher | John Wiley & Sons, Inc John Wiley and Sons Inc Wiley |
| Publisher_xml | – name: John Wiley & Sons, Inc – name: John Wiley and Sons Inc – name: Wiley |
| References | 2020; 8 2018; 7 2009; 14 2011; 378 1973; 22 2019; 21 2018; 104 2013; 41 2016; 388 2016; 54 2021; 384 2009; 5 2017; 243 2016; 25 2011; 331 2018; 46 e_1_2_9_20_1 e_1_2_9_11_1 e_1_2_9_22_1 e_1_2_9_10_1 e_1_2_9_21_1 e_1_2_9_12_1 e_1_2_9_8_1 e_1_2_9_7_1 e_1_2_9_6_1 e_1_2_9_5_1 e_1_2_9_4_1 e_1_2_9_3_1 e_1_2_9_2_1 e_1_2_9_9_1 e_1_2_9_15_1 Trivedi A (e_1_2_9_14_1) Trivedi A (e_1_2_9_13_1) e_1_2_9_17_1 e_1_2_9_16_1 e_1_2_9_19_1 e_1_2_9_18_1 |
| References_xml | – volume: 25 start-page: 117 issue: 1 year: 2016 end-page: 127 article-title: Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure publication-title: Expert Opin Investig Drugs – article-title: Effect of varying degrees of renal impairment on the pharmacokinetics of omecamtiv mecarbil [published online ahead of print March 26, 2021] publication-title: Clin Pharmacokinet – volume: 388 start-page: 2895 issue: 10062 year: 2016 end-page: 2903 article-title: Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC‐HF): a phase 2, pharmacokinetic, randomised, placebo‐controlled trial publication-title: Lancet – volume: 8 start-page: 329 issue: 4 year: 2020 end-page: 340 article-title: Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC‐HF publication-title: JACC Heart Fail – volume: 243 start-page: 465 year: 2017 end-page: 490 article-title: Direct myosin activation by omecamtiv mecarbil for heart failure with reduced ejection fraction publication-title: Handb Exp Pharmacol – volume: 384 start-page: 105 issue: 2 year: 2021 end-page: 116 article-title: Cardiac myosin activation with omecamtiv mecarbil in systolic heart failure publication-title: N Engl J Med – volume: 5 start-page: 211 issue: 2 year: 2009 end-page: 223 article-title: The Simcyp population‐based ADME simulator publication-title: Expert Opin Drug Metab Toxicol – volume: 46 start-page: 279 issue: 3 year: 2018 end-page: 290 article-title: Derivation of a system‐independent Ki for P‐glycoprotein mediated digoxin transport from system‐dependent IC50 Data publication-title: Drug Metab Dispos – volume: 331 start-page: 1439 issue: 6023 year: 2011 end-page: 1443 article-title: Cardiac myosin activation: a potential therapeutic approach for systolic heart failure publication-title: Science – volume: 22 start-page: 3099 issue: 23 year: 1973 end-page: 3108 article-title: Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction publication-title: Biochem Pharmacol – volume: 7 start-page: 1 year: 2018 end-page: 10 article-title: Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil publication-title: Drugs Context – volume: 378 start-page: 667 issue: 9792 year: 2011 end-page: 675 article-title: Dose‐dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first‐in‐man study publication-title: Lancet – volume: 104 start-page: 88 issue: 1 year: 2018 end-page: 110 article-title: Physiologically based pharmacokinetic model qualification and reporting procedures for regulatory submissions: a consortium perspective publication-title: Clin Pharmacol Ther – article-title: Pharmacokinetics, disposition, and biotransformation of [14C]‐omecamtiv mecarbil in healthy male subjects after a single intravenous or oral dose [published online ahead of print May 19, 2021] publication-title: Drug Metab Dispos – volume: 54 start-page: 217 issue: 3 year: 2016 end-page: 227 article-title: Relative bioavailability, food effect, and safety of the single‐dose pharmacokinetics of omecamtiv mecarbil following administration of different modified‐release formulations in healthy subjects publication-title: Int J Clin Pharmacol Ther – volume: 41 start-page: 1347 issue: 7 year: 2013 end-page: 1366 article-title: Variability in P‐glycoprotein inhibitory potency (IC(5)(0)) using various in vitro experimental systems: implications for universal digoxin drug‐drug interaction risk assessment decision criteria publication-title: Drug Metab Dispos – volume: 14 start-page: 289 issue: 4 year: 2009 end-page: 298 article-title: A novel approach to improve cardiac performance: cardiac myosin activators publication-title: Heart Fail Rev – volume: 21 start-page: 41 issue: 10 year: 2019 article-title: Statins in the prevention and treatment of heart failure: a review of the evidence publication-title: Curr Atheroscler Rep – ident: e_1_2_9_13_1 article-title: Effect of varying degrees of renal impairment on the pharmacokinetics of omecamtiv mecarbil [published online ahead of print March 26, 2021] publication-title: Clin Pharmacokinet – ident: e_1_2_9_21_1 – ident: e_1_2_9_6_1 doi: 10.1517/13543784.2016.1123248 – ident: e_1_2_9_18_1 doi: 10.1016/0006-2952(73)90196-2 – ident: e_1_2_9_4_1 doi: 10.1007/164_2017_13 – ident: e_1_2_9_7_1 doi: 10.1126/science.1200113 – ident: e_1_2_9_17_1 doi: 10.1002/cpt.1013 – ident: e_1_2_9_10_1 doi: 10.1016/S0140-6736(16)32049-9 – ident: e_1_2_9_2_1 doi: 10.1056/NEJMoa2025797 – ident: e_1_2_9_3_1 doi: 10.1016/j.jchf.2019.12.001 – ident: e_1_2_9_5_1 doi: 10.7573/dic.212518 – ident: e_1_2_9_20_1 – ident: e_1_2_9_14_1 article-title: Pharmacokinetics, disposition, and biotransformation of [14C]‐omecamtiv mecarbil in healthy male subjects after a single intravenous or oral dose [published online ahead of print May 19, 2021] publication-title: Drug Metab Dispos – ident: e_1_2_9_8_1 doi: 10.1007/s10741-009-9135-0 – ident: e_1_2_9_16_1 doi: 10.1517/17425250802691074 – ident: e_1_2_9_15_1 doi: 10.1007/s11883-019-0800-z – ident: e_1_2_9_9_1 doi: 10.1016/S0140-6736(11)61219-1 – ident: e_1_2_9_19_1 doi: 10.1124/dmd.112.050500 – ident: e_1_2_9_11_1 – ident: e_1_2_9_12_1 doi: 10.5414/CP202458 – ident: e_1_2_9_22_1 doi: 10.1124/dmd.117.075606 |
| SSID | ssj0063685 |
| Score | 2.284479 |
| Snippet | Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure. In vitro, OM is an inhibitor of BCRP.... Abstract Omecamtiv mecarbil (OM) is a novel cardiac myosin activator in development for the treatment of heart failure. In vitro, OM is an inhibitor of BCRP.... |
| SourceID | doaj pubmedcentral proquest pubmed crossref wiley |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 2510 |
| SubjectTerms | Adult ATP Binding Cassette Transporter, Subfamily G, Member 2 Biomedical Research Cardiovascular disease Congestive heart failure Coronary vessels Dosage Drug dosages Drug interaction Drug Interactions Ejection fraction Female Healthy Volunteers Heart failure Humans International organizations Investigations Kinases Laboratories Male Models, Biological Myosin Neoplasm Proteins Patients Pharmacokinetics Plasma Prescription drugs Rosuvastatin Calcium - pharmacokinetics Rosuvastatin Calcium - therapeutic use Urea - analogs & derivatives Urea - pharmacokinetics Urea - therapeutic use Vein & artery diseases Vital signs |
| SummonAdditionalLinks | – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3NbtQwELagSIgL4p-UggziwKGBrJ048QnRVasKCYSglfYW-S_Lim2yTXaReuMReDYegSdhxnECKwqnjexR1hOPxzP2zDeEPBeKK8dsHiuw5uMUvNpYWWNiUQkpMsth0_YBsu_F8Wn6dpbNwoFbF8IqB53oFbVtDJ6RvwIzXYI1k8r89eo8xqpReLsaSmhcJdcQugydr3w2OlwCwdV9QmQGqx5sk4AshJE8Zt29RKSZYms_8rD9l9maf4dM_mnK-r3o6Ba5GYxI-qaf9dvkiqvvkOvvwjX5XfLjcMTwpk1FbbuZ__z2HX8owkO0fTIDXTVrjBWCN4VoLdqcOaPOQANSfGj1YklVbSmMfPNVYe7Rot6nih5MP36gHagcD227T_EwF5qHLEvqMWvhr2ifZXmBtHje0_m3Yaj9HMj9ocqge5cXMELcUi2092jaX4AXYJD6Yj33yOnR4cn0OA7FG2KTeYxS5iYyNUZbUUjjmJYsl5rpPBE2FYlKbMYtV4WtClmBTVlJqZNMMS5cxZOk4vfJTt3U7iGhBfRhqV5WZCIFeq0Zy5XOFOd64vJJRF4MU1iagGyOBTaW5eDhAIOln-2IPBtJVz2cx2VEBygHIwEicPuGpp2XYUGXhVCKOZmrivFUWoGOI8drTl1YlwkZkb1BisqgFrrytxBH5OnYDQsab2lU7ZoN0gieMvDE04g86IVuHAlH71fkPCL5ljhuDXW7p1589qDhhcBL7gS-lRfcf3NfTk8--Yfd_3PwiNxgGN_j8zL3yM663bjHYKCt9RO_Cn8B3alAmA priority: 102 providerName: ProQuest – databaseName: Wiley Online Library Open Access dbid: 24P link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwEB6VIiEuiH9CCzKIA4cGZW3HicWJrlpVSKAKWqm3yI6dZcU2qTa7SL31EXg2HoEnYcb5UVcUiVMie5LY8cx4xp75DPBGGWE8d1ls0JqPJXq1sXFlGatKaZU6gZN2CJD9rI5O5cez9GwL3g-5MB0-xLjgRpIR9DUJuLHtNSEvV-07worJb8FtSq0lJufyeFDDipDVQzZkiiKPhkkPK0RhPOOjG5NRwOy_ydD8O17yuh0bJqLD-3CvtyDZh27IH8CWrx_CnU_9Hvkj-HUwAnizpmJuuZ79vvpJF0bYEMsuk4FdNCsKFMI39aFarDn3pTlH9cfoZmnnC2Zqx7Dl6x-GEo_m9R4zbH_65Zi1qG8Cru0eo5VcLB5SLFkArMVPsS7F8pJoabGnDW-jOPsZkocVlUHxLi6xhTSfOizvoLS_Y1-wgyyc1PMYTg8PTqZHcX9yQ1ymAaCU-4mWZWmdynXpudU805bbLFFOqsQkLhVOmNxVua7QoKy0tklquFC-EklSiSewXTe1fwYsxzo6p5fnqZJIby3nmbGpEcJOfDaJ4O0whEXZw5rT6RqLYnBvsINFGO0IXo-kFx2Wx01E-8QHIwHBb4eCZjkremkucmUM9zozFRdSO0Veo6A9Tps7nyodwe7ARUWvE9oCHU2N9rjUWQSvxmqUZtqiMbVv1kSjhOTohssInnZMN7ZEkOurMhFBtsGOG03drKnn3wJieK5ohzvBfxUY99-9L6YnX8PN8_8n3YG7nAJ9QoLmLmyvlmv_Ai21lX0ZJPIP4tpAjA priority: 102 providerName: Wiley-Blackwell |
| Title | Evaluation of drug‐drug interaction potential between omecamtiv mecarbil and rosuvastatin, a BCRP substrate, with a clinical study in healthy subjects and using a physiologically‐based pharmacokinetic model |
| URI | https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fcts.13118 https://www.ncbi.nlm.nih.gov/pubmed/34415673 https://www.proquest.com/docview/2599099497 https://www.proquest.com/docview/2563422104 https://pubmed.ncbi.nlm.nih.gov/PMC8604240 https://doaj.org/article/86aa2e97af2349d6999630760b8de569 |
| Volume | 14 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbtQwELagSIgL4p9AWRnEgUMDWdux4yO72qpColqVVtpbZMdOu2KbVPtTqbc-As_GI_AkzDg_6ooiLlySyB4ltjMez9gz3xDyXhpuPHMqNqDNxwKs2ti4oohlKbVMHYdFOzjIHsqDE_Flls5upPpCn7AGHrgZuE-ZNIZ5rUzJuNBOooLO8TjJZs6nMoTuwZrXGVONDJYIqx5CIVOY76CVtJhC6MNTrFcfEWMm21qJAmD_bVrmn86SN5XYsArtPyIPW_WRfm6a_Zjc8dUTcv9re0D-lPyc9OjdtC6pW25Of13_wBtFYIhlE8ZAL-o1egnBm1o_LVqf-8Kcg-yj-LC08wU1laPQ8s2lwaijebVHDR2Nj6Z0BcImgNruUdzGheIuvpIGtFr4FG3iK6-QFnd6VuFt6GR_CuRhO6WTuosraCEupg7KGxzt79AX6CANaXqekZP9yfH4IG7TNsRFGtBJmR9qURTWyUwXnlnNlLbMqkQ6IROTuJQ7bjJXZroEbbLU2iapYVz6kidJyZ-Tnaqu_EtCM6jDJL0sS6UAemsZU8amhnM79GoYkQ_dL8yLFtMcU2ss8s62gQ7m4W9H5F1PetEAedxGNEI-6AkQezsUAEfmLUfm_-LIiOx2XJS3AmGVg5WpQRkXWkXkbV8NUxnPZ0zl6w3SSC4Y2OAiIi8aputbwtHulYpHRG2x41ZTt2uq-VmAC88kHm8nMFaBcf_e-3x8_C08vPofw_CaPGDo_xPiNnfJznq58W9AgVvbAbnLxBSuaqYG5N5ocjg9GoT5-xtFJUt8 |
| linkProvider | Directory of Open Access Journals |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELZKkaAXxD-BAgaBxKGB1E6c-IAQXVpt6Y8QbKW9pXbsbFdsk2V_QHvjEXgSHoZH4EmYcX5gReHW00b2yGvHk_GMZ-YbQp4IxZVlJvYVaPN-CFatr0yW-SIXUkSGw6HtAmQPRfcofNuP-ivke5MLg2GVjUx0gtqUGd6RvwA1XYI2E8r41fiTj1Wj0LvalNCo2GLPLr6AyTZ9ufsG9vcpYzvbvU7Xr6sK-FnkwDOZBcM9y7QRicws05LFUjMdB8KEIlCBibjhKjF5InNQdnIpdRApxoXNeRDkHMa9QC7CwRtgCGHcbw08gWDuLgEzAikDulCNZISRQ9ls-hyRbZKl88-VCThLt_07RPNP1dmdfTtXyZVaaaWvKy67RlZscZ1cOqjd8jfIj-0WM5yWOTWT-eDn12_4QxGOYlIlT9BxOcPYJBipjg6j5anN1ClIXIoPEz0cUVUYCjOff1aY6zQsNqiiW5337-gURJyD0t2geHkMzU1WJ3UYufBXtMrqXCAt3i9N3WgY2j8AcneJ08j60QJmiEe4gfYKvfsjrAUWSF1xoJvk6Fy29RZZLcrC3iE0gT4sDcySSIRArzVjsdKR4lxv2njTI8-aLUyzGkkdC3qM0saiggWmbrc98rglHVfwIWcRbSEftASI-O0ayskgrQVImgilmJWxyhkPpRFoqHJ0q-rE2EhIj6w3XJTWYmia_v5oPPKo7QYBgl4hVdhyjjSChwws_9Ajtyuma2fC0doWMfdIvMSOS1Nd7imGJw6kPBHoVA_gXTnG_ffq007vg3u4-_8VPCSXu72D_XR_93DvHlljGFvkckLXyepsMrf3QTmc6Qfui6Tk-LxFwC85qHzj |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3NbtQwELZKkSouiH8CBQwCiUNDUztx4gNCdNtVS6GqoJX2FuzYWVZskyW7C9obj8Dz8Bg8Ak_CjPMDKwq3nhLZI8eOx-MZe-YbQh4LxZVlJvYVaPN-CFatr0yW-SIXUkSGw6btHGQPxd5J-GoQDVbI9zYWBt0qW5noBLUpMzwj3wQ1XYI2E8p4M2_cIo52-i8mn3zMIIU3rW06jZpFDuziC5hv0-f7OzDXTxjr7x739vwmw4CfRQ5Ik1kw4rNMG5HIzDItWSw103EgTCgCFZiIG64SkycyB8Unl1IHkWJc2JwHQc6h3QvkYsxh24S1FA86Y08gsLsLxoxA4oBe1KAaoRdRNps-Q5SbZGkvdCkDztJz_3bX_FONdvtg_wq53Ciw9GXNcVfJii2ukbU3zRX9dfJjt8MPp2VOTTUf_vz6DR8UoSmqOpCCTsoZ-ilBS42nGC1PbaZOQfpSfKn0aExVYSj0fP5ZYdzTqNigim733h7RKYg7B6u7QfEgGYrbCE_q8HLhU7SO8FwgLZ41TV1r6OY_BHJ3oNPK_fECeojbuYHyGsn7I4wFBkhdoqAb5ORcpvUmWS3Kwt4mNIE6TBPMkkiEQK81Y7HSkeJcb9l4yyNP2ylMswZVHZN7jNPWuoIBpm62PfKoI53UUCJnEW0jH3QEiP7tCspqmDbCJE2EUszKWOWMh9IINFo5XrHqxNhISI-st1yUNiJpmv5eQB552FWDMMEbIlXYco40goeMgYnukVs103U94Wh5i5h7JF5ix6WuLtcUow8OsDwReMEewL9yjPvv0ae943fu5c7_R_CArMHiT1_vHx7cJZcYuhm58NB1sjqr5vYe6Ikzfd8tSEren7cE-AXBtYEZ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+drug%E2%80%90drug+interaction+potential+between+omecamtiv+mecarbil+and+rosuvastatin%2C+a+BCRP+substrate%2C+with+a+clinical+study+in+healthy+subjects+and+using+a+physiologically%E2%80%90based+pharmacokinetic+model&rft.jtitle=Clinical+and+translational+science&rft.au=Ashit+Trivedi&rft.au=Winnie+Sohn&rft.au=Priyanka+Kulkarni&rft.au=Pegah+Jafarinasabian&rft.date=2021-11-01&rft.pub=Wiley&rft.issn=1752-8054&rft.eissn=1752-8062&rft.volume=14&rft.issue=6&rft.spage=2510&rft.epage=2520&rft_id=info:doi/10.1111%2Fcts.13118&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_86aa2e97af2349d6999630760b8de569 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1752-8054&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1752-8054&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1752-8054&client=summon |